ABSTRACT
Background Much of the testing performed by clinical laboratories does not translate into benefit for patients. To reduce the number of these low-value tests, laboratories use different intervention strategies, trying to adapt the analytical demand to clinical needs. The effectiveness of these interventions is usually evaluated through indicators related to the activity or cost rather than the benefit they imply for patients.
Methods We have derived expressions that relate the fraction of patients tested (Rt) and the abnormal result rate (Ra) obtained by the requesting physician with the net benefit that the use of the test represents for both tested and untested patients.
Results The behavior of physicians regarding the use of a test in each healthcare context and the effect of an intervention on this behavior can be characterized by these two parameters: Ra and Rt. An increase in the value of Ra implies a greater net benefit for all patients attended. When the physician is selective in the use of the test, an increase in the value of Rt implies a greater benefit for untested patients but represents a limit to the increase in Ra.
Conclusions Interventions aimed at reducing the demand for tests should act primarily by increasing selectivity in the use of tests, increasing the benefit for the patients tested and compensating the harm that the reduction in testing entails for patients who are not.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
Nonstandard abbreviations
- Ra
- abnormal result rate
- Rt
- fraction of tested patients
- NBT
- net benefit for the tested patient
- NBU
- net benefit for the untested patient
- PT
- prevalence of the investigated disease among the tested patients
- PU
- prevalence of the investigated disease among the untested patients
